181 unknown. 181 Phase 2, 58 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 181 | Unknown 181 |
| Phase 1 | 58 | Unknown 58 |
| Phase 3 | 6 | Unknown 6 |
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL Polatuzumab vedotin, Rituximab, Orelabrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Affiliated Hospital of Nantong University | 30 | 2024-08-01 | 2025-02-04 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). Azacitidine Injection, Venetoclax, CD19CD22 CAR-T - B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2024-04-20 | 2024-04-22 |
| CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors CD19&CD20 bispecific CAR-T cells - B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-01-14 | 2024-07-16 |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma Obinutuzumab Combined With Bendamustine - B Cell Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2023-11-30 | 2024-05-16 |
| A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma SHR-A1912; R-Chemo - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 132 | 2023-11-17 | 2023-12-27 |
| Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL ZR2-ICE - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-10-12 | 2024-03-13 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma CD19-targeted Chimeric Antigen Receptor(CAR) T Cells - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 10 | 2023-08-17 | 2024-08-21 |
| Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors Zanubrutinib, Rituximab, Cyclophosphamide - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Liaoning Cancer Hospital & Institute | 30 | 2023-08-01 | 2023-07-27 |
| Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab vedotin and Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Peng Liu | 35 | 2023-07-20 | 2023-07-11 |
| Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Mitoxantrone Hydrochloride Liposome Injection - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 104 | 2023-07-10 | 2024-02-08 |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| A Combination Study of CAR-T Therapy in r/r B-NHL BTK inhibitor, PD-1 inhibitor - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 48 | 2023-06-10 | 2023-08-01 |
| Decitabine and Anti-PD-1 in R/R DLBCL Low-Dose Decitabine plus anti-PD-1 - Diffuse Large B Cell Lymphoma, Relapse/Recurrence | Phase 2 | Unknown | Chinese PLA General Hospital | 20 | 2023-05-15 | 2023-05-09 |
| Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma ThisCART19A, Fludarabine, Cyclophosphamide - Refractory or Relapsed B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Chongqing University Cancer Hospital | 12 | 2023-05-01 | 2023-03-20 |
| A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide IMM0306, Lenalidomide capsule - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 102 | 2023-05-01 | 2023-05-24 |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers BR1733 - Advanced Cancer, Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Blueray Biopharma Co., Ltd. | 191 | 2023-04-19 | 2024-08-07 |
| Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI Orelabrutinib combined with R-CDOP regimen - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 62 | 2023-03-30 | 2024-03-04 |
| Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - B-cell Lymphoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 20 | 2023-01-03 | 2024-01-08 |
| Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells regimen with BTK inhibitor +Anti-CD19 CAR T cells - B-cell Non Hodgkin Lymphoma | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 30 | 2023-01-01 | 2023-02-24 |
| Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma CD19 and CD22 targeted CAR-T cells - Lymphoma, B-Cell | Phase 1 / Phase 2 | Unknown | Kecellitics Biotech Company Ltd | 50 | 2022-12-10 | 2022-12-14 |
Showing 20 of 181. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (106) · Burkitt Lymphoma (39) · Lymphoma (34) · Lymphoma, Follicular (32) · Recurrence (27) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Lymphoma, Non-Hodgkin (25) · Lymphoma, B-Cell, Marginal Zone (24) · Lymphoma, Mantle-Cell (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (22) · Lymphoma, Large-Cell, Immunoblastic (13) · Leukemia (12) · Leukemia, B-Cell (9) · Multiple Myeloma (9)
Hemic and Lymphatic Diseases (181) · Lymphatic Diseases (180) · Lymphoproliferative Disorders (180) · Immune System Diseases (179) · Immunoproliferative Disorders (179) · Neoplasms by Histologic Type (179) · Neoplasms (177) · Lymphoma, Non-Hodgkin (156) · Lymphoma (147) · Hematologic Diseases (49) · Disease Attributes (48) · Pathologic Processes (48) · Pathological Conditions, Signs and Symptoms (48) · Leukemia, Lymphoid (44)
Rituximab (45) · Cyclophosphamide (35) · Lenalidomide (15) · Vincristine (15) · Doxorubicin (14) · Cytarabine (13) · Prednisone (13) · Etoposide (12) · Antigens, CD19 (8) · Dexamethasone (8) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (8) · Gemcitabine (7) · Immunotherapy, Adoptive (7) · fludarabine (7) · zanubrutinib (7)
Chinese PLA General Hospital (7) · Ruijin Hospital (7) · Fudan University (5) · The First Affiliated Hospital of Soochow University (5) · The First Affiliated Hospital with Nanjing Medical University (5) · Asan Medical Center (4) · Chongqing Precision Biotech Co., Ltd (4) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3) · Huiqiang Huang (3) · Nanfang Hospital, Southern Medical University (3) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · Shenzhen BinDeBio Ltd. (3) · Wuhan Sian Medical Technology Co., Ltd (3) · Auxilio Mutuo Cancer Center (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)
China (107) · United States (22) · South Korea (8) · Italy (5) · Israel (4) · United Kingdom (4) · Canada (3) · Puerto Rico (3) · Australia (2) · Austria (2) · Germany (2) · Russia (2) · Spain (2) · Sweden (2) · Switzerland (2)
Cheng Qian, PhD (4) · Sanbin Wang, MD (4) · David G. Savage, MD (2) · Fernando Cabanillas, MD (2) · Jieping Chen, MD,PhD (2) · Jun Zhu, MD (2) · Li Yu, Dr (2) · Michele Spina, MD (2) · Ron Ram, Prof. (2) · YU HU, M.D., Ph.D (2) · Ye Guo, MD (2) · A. McMillan (1) · Anthony D Ho, Ph.D., Prof. (1) · Baorui Liu, MD (1) · Barbara Pro, MD (1)
PMID 34515338, PMID 40195173, PMID 15107815, PMID 18213528, PMID 18824292, PMID 1950172, PMID 20686505, PMID 21390126, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 22899582, PMID 23228045, PMID 23753028, PMID 23799873, PMID 24382970, PMID 24721323, PMID 24963497, PMID 25444722, PMID 25652253, PMID 25712263, PMID 28054442, PMID 28356247, PMID 29263894, PMID 29748444, PMID 29752199, PMID 30620669, PMID 30896447, PMID 31039052, PMID 32187361, PMID 32245502, PMID 32464282, PMID 32580597, PMID 32989495, PMID 33097085, PMID 33382529, PMID 34568066, PMID 34893603, PMID 35418080, PMID 35799791, PMID 36053875, PMID 36102758, PMID 36842849, PMID 37560813, PMID 38237077, PMID 38579729, PMID 39319495, PMID 39396632, PMID 39572395
2005 (1), 2009 (1), 2015 (1), 2016 (1), P30CA015083 (1), P30CA060553 (1)